Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.